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Abstract
There has been an increasing interest in using interval-based Bayesian designs for dose finding, one
of which is the modified toxicity probability interval (mTPI) method. We show that the decision rules
in mTPI correspond to an optimal rule under a formal Bayesian decision theoretic framework. However,
the probability models in mTPI are overly sharpened by the Ockham’s razor, which, while in general
helps with parsimonious statistical inference, leads to suboptimal decisions in small-sample inference
such as dose finding. We propose a new framework that blunts the Ockham’s razor, and demonstrate
the superior performance of the new method, called mTPI-2. An online web tool is provided for users
who can generate the design, conduct clinical trials, and examine operating characteristics of the designs
through big data and crowd sourcing.
Keywords: Bayes rule; Big data; Crowd sourcing; Decision theory; Phase I clinical trial.
1 Introduction
Often, phase I trials in diseases like cancer, osteoarthritis, and psoriasis aim to find the maximum tolerated
dose (MTD), the highest dose with toxicity rate lower than or close to a pre-specified target level, pT . As
in most statistical inference, an estimated MTD is usually produced to represent the true and unknown
MTD. However, the estimation is always with noise and the probability of toxicity for the estimated MTD
is never exactly the same as pT . For this reason, the statistical community has been considering interval-
based inference to account for the variabilities in the toxicity estimates. For example, Cheung and Chappell
(2002) propose to treat any dose with toxicity probability in the “indifference interval” (pT − δ, pT + δ) as
an estimated MTD, as long as a small δ ∈ (0, 1) is agreed upon at the design stage by the clinical team.
Later, in Ji et al. (2007, 2010) and Ji and Wang (2013), the authors further developed toxicity probability
interval (TPI) and modified TPI (mTPI) methods, in which they formally proposed a decision theoretic
framework linking the dose-finding decisions of “Stay” (S), “De-escalation” (D), and “Escalation” (E) with
the equivalence interval EI = (pT − 1, pT + 2), over-dosing interval OI = (pT + 2, 1), and under-dosing
interval UI = (0, pT − 1), respectively. For a given dose d, the authors calculate Pr(pd ∈ EI | data),
Pr(pd ∈ OI | data), and Pr(pd ∈ UI | data), three posterior probabilities that the toxicity rate pd belongs to
each of the three dosing intervals. The authors associate the dose-finding decisions with these three posterior
probabilities. Distinctively, inference in mTPI is directly linked to the posterior probabilities of the three
dosing intervals, which is different from a class of other interval designs (Ivanova et al., 2007; Oron et al.,
2011; Liu and Yuan, 2015) that use a point estimate pˆd and compare pˆd with three dosing intervals. That is,
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these interval designs do not directly calculate posterior probabilities of the intervals. They use the intervals
as a thresholding device where their inference is still based on a point estimate of pd.
Interval-based designs, such as mTPI (Ji et al., 2010) are based on parametric models and use model-based
inference for decision making. In Ji and Wang (2013) and Yang et al. (2015) the superiority of the interval-
based designs over the standard rule-based designs, such as the 3+3 design is established using massive
simulations and crowd sourcing. One critical and distinctive feature of mTPI is its ability to precalculate
all the dose finding decisions in advance, allowing investigators to examine the decisions before the trial
starts. Therefore, even though a model-based design, mTPI exhibits the same simplicity and transparency
as rule-based methods.
However, some decision rules in mTPI could be debated in practice. For example, when the target toxicity
probability pT = 0.3, and 3 out of 6 patients treated at a dose experience dose limiting toxicity (DLT) events,
mTPI would suggest “S”, stay at the current dose and enroll more patients to be treated at the dose. Since
the empirical rate is 3/6, or 50%, practitioners have argued that the decision should be “D”, de-escalation
instead of “S”. Another case is when pT = 0.3 and 2 out of 9 patients experience DLT events at a dose,
mTPI would suggest “S” as well. Investigators could argue that the decision should be “E”, escalation since
the empirical rate is 2/9, or 22%. For this reason, Yang et al. (2015) proposed an ad-hoc remedy that allows
the decision rules in the mTPI design to be modified by users. While this feature allows great flexibility in
practice, it lacks solid statistical justification and therefore cannot be properly assessed.
To this end, we propose mTPI-2, an extension of mTPI that solves the undesirable issue in the current
decision under mTPI. We show that the suboptimal rules listed above are consequences of the Ockham’s
razor (Jefferys and Berger, 1992). The Ockham’s razor usually helps Bayesian inference to automatically
achieve parsimony by favoring simpler models. However, in the case of dose finding with small sample size,
the Ockham’s razor is too sharp and must be blunted. Otherwise, anti-intuitive decisions, such as those
listed above, will be generated as a consequence of parsimonious inference under the Ockham’s razor. In
mTPI-2, we provide a new framework to blunt the Ockham’s razor, which leads to an improved decision
table.
The remainder of the paper is organized as follows. Section 2 is devoted to Ockham’s razor and its role
in interval-based designs. Section 3 proposes mTPI-2 as a solution to blunt the Ockham’s razor with a few
simple theoretical results. Section 4 examines the numerical performance of mTPI-2, in comparison to the
mTPI design using crowd sourcing. Section 5 introduces an online software that implements both methods
and Section 6 ends the manuscript with a discussion.
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2 Ockham’s Razor and Interval-Based Designs
As an accepted principle in science, the Ockham’s razor states the principle that an explanation of the facts
should be no more complicated than necessary (Thorburn, 1918; Jefferys, 1990; Good, 1967; MacKay, 1992;
Jefferys and Berger, 1992). A direct impact of Ockham’s razor is on model selection, which favors “smaller”
models if data can be fit similarly well by different models.
Usually, in model selection one considers multiple models {Mi; i = 1, . . . , I}, and for each model Mi, a
set of parameters θi. Bayesian inference involving model selection typically requires a prior p(Mi) for the
candidate model i and a prior p(θi | Mi) for parameters θi that characterize the parameters of interests in
model Mi. Formal posterior inference calculates the posterior probability of the model p(Mi | data) and
selects the model with the largest posterior probability. Numerous papers have shown that the inference
based on the posterior probability p(Mi | data) automatically applies the Ockham’s razor, in that models
with more parameters and larger parameter space are penalized.
In general, the Ockham’s razor helps Bayesian inference by selecting more parsimonious models. However,
in the case of interval-based designs for dose finding, such as mTPI, Ockham’s razor is too sharp and leads
to practically undesirable decisions. To see this, we first conduct a quick review of the mTPI design.
The mTPI design considers three intervals that partition the sample space (0, 1) for the probability of
toxicity pd at a given dose d:
ME : pd ∈ (0, pT − 1)
MS : pd ∈ (pT − 1, pT + 2)
MD : pd ∈ (pT + 2, 1) (1)
The three intervals can be viewed as three models Mi with index i ∈ {E,S,D}, where the three letters
correspond to the dose-finding decisions if they are selected. For example, when ME is selected as the
winning model, the corresponding decision is “E”, to escalate from the current dose. Typically, pT ranges
from 0.1 to 0.3 in phase I trials, and ’s are usually small, say ≤ 0.05. In mTPI, the observed data are
integers (xd, nd), where nd and xd represent the numbers of patients treated at dose d and those who have
experienced DLT events, respectively. Given pd, the probability of toxicity at dose d, xd | pd ∼ Bin(nd, pd)
a binomial distribution. The mTPI design assumes that pd ∼ Beta(1, 1), and the dose-finding decision rule
for dose d is given by
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DmTPI = arg max
i∈{E,S,D}
UPM(i, d) (2)
where
UPM(i, d) =
Pr(Mi | {xd, nd})
S(Mi)
(3)
is the posterior probability of the interval Mi divided by the length of the interval.
We first show that the decision rule DmTPI is optimal if intervals Mi are considered part of the
candidate models in a model-selection framework. To see this, we introduce an additional parameter
md ∈ {ME ,MS ,MD}, which denotes the indicator of the three candidate models (intervals) to which pd
belongs. In particular, Theorem 1 below shows that decision DmTPI corresponds to the Bayes rule, the
optimal decision rule that minimizes the posterior expected loss under a 0-1 loss function `(a,md) (Berger,
1988), defined by
`(a = i,md = Mj) =
 1, if i 6= j;0, if i = j, for i, j ∈ {E,S,D}. (4)
The loss function `(a,md) states that the loss for taking action i is 0 if model Mi is the winning model, and
1 otherwise.
Theorem 1. Given the sampling model xd | pd ∼ Bin(nd, pd) and priors
pd | md = Mi ∼ 1
S(Mi)
I(pd ∈Mi)
p(md = Mi) =
1
3
independently for all doses, and given the 0-1 loss function `(i,Mj) in (4) for three decisions, where i, j ∈
{E,S,D}, decision rule DmTPI in (2) is optimal in the sense that it minimizes the posterior expected loss.
Proof is given in the Appendix A.
The Bayes rule DmTPI selects the action i ∈ {E,S,D} corresponding to the model Mi with the largest
posterior probability. This inference is subject to Ockham’s razor. As an example, when xd = 3 and
nd = 6, i.e., the decision rule DmTPI boils down to comparing the UPM(S, d) and UPM(D, d), which
involves the calculation of the posterior probability Pr(Mi | xd, nd) for MS = (pT − 1, pT + 2) and
MD = (pT + 2, 1). For each model, the size of the model is the length of the interval in the model. The
model size S(MD) = (1− pT − 2) is usually larger than the size S(MS) = (1 + 2) since usually pT is close
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to 0.3 or 0.16, and 1,2 ≤ 0.05.. The posterior probability Pr(Mi | xd, nd) can be written as a difference
of incomplete beta functions evaluated at the boundaries of the two models. Some theoretical discussion of
how Pr(Mi | xd, nd) depends on xd, nd and interval definitions are given in Appendix B. When xd = 3 and
nd = 6, it can be shown that the UPM(S, d) is larger than UPM(D, d) for pT = 0.3 and 1 = 2 = 0.05.
Consequently, even though the empirical rate xd/nd = 0.5 is greater than pT = 0.3, mTPI still prefers S, to
stay at the current dose. In summary, due to the Ockham’s razor which prefers more parsimonious model, in
this case model MS with a shorter interval length, mTPI chooses to stay at dose d when xd = 3 and nd = 6.
Theoretically, the exact proof depends on the convexity of the incomplete beta function, which is still an
open question (Swaminathan, 2007) with no conclusion. Instead, we provide a numerical illustration next.
As an example that shows the effect of the Ockham’s razor, in Figure 1, mTPI will select decision “S”
even when xd = 3 out of nd = 6 patients experience the DLT events, and the posterior distribution is clearly
peaked inside the interval MD.
3 A Solution to Blunt the Ockham’s Razor: mTPI-2
3.1 Decision theoretic framework
We provide a solution to blunt the Ockham’s razor for mTPI and avoid the undesirable decisions, such as
S when 3 out of 6 patients experience DLT at a given dose. Statistically speaking, there is nothing wrong
with the current decision in mTPI as the Bayesian inference takes into account the model complexity when
choosing the optimal decision. However, for human clinical trials patient safety often outweighs statistical
optimality. To this end, we modify the decision theoretic framework and blunt the Ockham’s razor.
We call the new class of designs mTPI-2, since the framework is motivated by that in mTPI. We show
next that the framework blunt the Ockham’s razor and leads to safer and more desirable decision rules.
Importantly, mTPI-2 preserves the same simple and transparent nature exhibited in mTPI, facilitating its
practical implementation by both statisticians and clinicians.
The basic idea is to divide the unit interval (0, 1) into subintervals with equal length, given by (1 + 2).
This results in multiple intervals with the same length, which are considered multiple equal-sized models.
See Figure 2. For clarity, we now denote EI the equivalence interval (pT − 1, pT + 2), and LI a set of
intervals below EI, and HI a set of intervals above EI. For example, when pT = 0.3 and 1 = 2 = 0.05,
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Figure 1: An example demonstrating the effect of the Ockham’s razor in mTPI. Shown is the posterior
density of pd when xd = 3 and nd = 6. Even though the shape of the density suggests that dose d might
be above the MTD, e.g., the posterior mode is to the right of the equivalence interval (shown as the two
vertical bars), the UPM for decision S (stay) is still larger than that the UPM for decision D (de-escalate).
Therefore, mTPI would still choose to “Stay” despite that the shape of the posterior density of pd indicates
otherwise. This is due to the larger size (longer length) of the interval MD than MS and the Ockham’s razor,
which prefers the smaller model MS .
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the equivalence interval is EI = (0.25, 0.35), the LI intervals are
LI = {MLI1 = (0.15, 0.25), MLI2 = (0.05, 0.15), MLI3 = (0, 0.05)},
and the HI intervals are
HI = {MHI1 = (0.35, 0.45), MHI2 = (0.45, 0.55), MHI3 = (0.55, 0.65), MHI4 = (0.65, 0.75),
MHI5 = (0.75, 0.85),M
HI
6 = (0.85, 0.95), M
HI
7 = (0.95, 1)}.
The same as mTPI, if the equivalence interval MEI = (pT −1, pT +2) has the largest UPM, it is selected as
the winning model and the dose-finding decision of mTPI-2 is S, stay. If any interval MHIi or M
LI
i has the
largest UPM, it will be selected as the winning model and the dose-finding decision is D or E, respectively.
In Figure 2, for the same posterior density corresponding to xd = 3 and nd = 6, interval M
HI
2 exhibits the
largest UPM and therefore the decision is now D. Note that the same decision theoretic framework as mTPI
is in place except that now there are multiple intervals corresponding to D or E, and the intervals all have
the same length, thereby blunting the Ockham’s razor.
3.2 Optimal rule for mTPI-2
We again consider a 0-1 loss function l(a,md), but with multiple intervals, and multiple decisions. Shown in
Table 1 the loss function divides the parameter space (0, 1) of pd into (k1 + k2 + 3) intervals, with (k1 + 1)
intervals below the equivalence interval MEI and (k2+1) intervals above M
EI . Except for the two boundary
intervals MLIk1+1 and M
HI
k2+1
, all the intervals have the same length δ = (1+2). The loss l(a,md) is a function
of action a that selects any of the (k1 +k2 +3) intervals as the winning model, and the parameter md indexes
the model, which takes one of the intervals Mi.
There are a total of (k1 + k2 + 3) intervals. Consider the statistical decision a to select one interval
as the winning interval into which the toxicity probability pd falls. However, selecting a winning interval
must be translated into dose-finding decisions. To this end, we consider a deterministic mapping. Define
a∗ ∈ {E,S,D} the three dose-finding decisions for the trial. Based on ethical consideration, whenever the
statistical decision a is in set LI, EI, or HI, the corresponding trial decision a∗ takes value E, S, or D,
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Figure 2: An example demonstrating the new framework of mTPI-2. Here, EI is the equivalence interval
(pT − 1, pT + 2), and LI denotes the intervals below EI, and HI denotes the intervals above EI. Interval
MHI2 exhibits the largest UPM and therefore the decision is now D, to de-escalate.
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respectively. Mathematically, this means that
a∗ =

E, if a ∈ LI
S, if a = EI
D, if a ∈ HI.
(5)
The goal is to optimally select a, which leads to a∗.
Table 1: A loss function of dose finding decisions a and model parameter md. Columns are the sample space
of md, i.e., the candidate models are the toxicity probability intervals and rows are the action values for a
and a∗ (5).
Loss function `(a,md), for a to select a model ∈ {LI,EI,HI} and md also takes an interval value ∈ {LI,EI,HI}.
md ∈ LI: Intervals below the Equiv. Interval md = EI: Equiv. Interval md ∈ HI: Intervals above Equiv. Interval
Actions a, a∗ MLIk1+1 = (0, pT − 1 − k1δ) · · · MLI1 = (pT − 1 − δ, pT − 1) MEI = (pT − 1, pT + 2) MHI1 = (pT + 2, pT + 2 + δ) · · · MHIk2+1 = (pT + 2 + k2δ, 1)
a = MLI1 , a
∗ = E 0 1 1 1 1 1 1
· · · · · ·
a = MLIk1+1, a
∗ = E 1 1 0 1 1 1 1
a = MEI , a∗ = S 1 1 1 0 1 · · · 1
a = MHI1 , a
∗ = D 1 1 1 1 0 1 1
· · · · · ·
a = MHIk2+1, a
∗ = D 1 1 1 1 1 · · · 0
Assume that given nd, xd follows a binomial distribution, i.e., f(xd | nd, pd) ∝ pxdd (1− pd)nd−xd . For pd,
given interval (model) md = Mi, assume a prior
pd | md = Mi ∼ Beta(1, 1)I(pd ∈Mi). (6)
Assume prior probability p(md = Mi) is the same for all the models (intervals), where Mi ∈ ∪{LI,EI,HI}.
Theorem 2 below provides the optimal decision rule for mTPI-2.
Theorem 2. The new Bayes rule DmTPI-2 ≡ Da∗ that takes action a∗ ∈ {E,S,D} corresponds to the
Bayes rule Da that takes actions a ∈ {LI,EI,HI}. Under `(a,md) in Table 1 and the hierarchical model
{f(xd | nd, pd), f(pd | md), p(md)} above, DmTPI-2 is given by the following rule:
• If Mmax ≡ arg maxi Pr(md = Mi | {xd, nd}) = EI, DmTPI-2 = S, to Stay.
• If Mmax ≡ arg maxi Pr(md = Mi | {xd, nd}) ∈ LI, DmTPI-2 = E, to Escalate.
• If Mmax ≡ arg maxi Pr(md = Mi | {xd, nd}) ∈ HI, DmTPI-2 = D, to De-escalate.
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Proof is immediate given the fact that Da is the Bayes rule for the loss function in Table 1 and the definition
in (5).
Theorem 2 states that the optimal rule is to first find the interval Mmax with the largest posterior
probability. If Mmax is the EI, the equivalence interval, stay at the current dose and treat the next cohort of
patients at that dose; if Mmax is one of the intervals in LI, escalate to and treat the next cohort of patients
at the next higher dose; if Mmax is one of the intervals in HI, de-escalate to and treat the next cohort of
patients at the next lower dose. This decision rule minimizes the Bayes risk, i.e., the posterior expected loss.
Corollary 1: The optimal decision DmTPI−2 is equivalent to the following procedure: Assume dose d is the
current dose being used for treatment.
1. Compute UPM(i, d) in (3) for each interval Mi ∈ ∪{LI,EI,HI}. Let Mmax be the interval with the
largest UPM .
2. If Mmax is the EI, in LI, or in HI, the optimal rule DmTPI−2 is to Stay, Escalate, or De-escalate,
respectively.
Proof: It suffices to prove Pr(md = Mi | {xd, nd}) = UPM(i, d), which is immediate.
3.3 Design Algorithm
The implementation of the mTPI-2 design is as simple and transparent as mTPI. A decision table of all the
optimal decisions in Corollary 1 can be precalculated. See Figure 3 as an example for a trial with pT = 0.3
and 1 = 2 = 0.05. The table in Figure 3(a) guides all the dose assignment decisions throughout the trial.
For example, suppose a trial has five candidate doses, and dose 3 is being used to treat patients. Then the
possible doses for treating future patients are doses 2, 3, and 4. Record n3 and x3 as the number of patients
treated and number of patients experienced DLT at dose 3, then go to the table entry corresponds to row
x3 and column n3, and treat the next cohort of patients based on the decision in the table. For example, if
x3 = 3 and n3 = 6, the decision is D in Figure 3(a), and the next patients will be treated at dose 2. Note
that in contrast, Figure 3(a) would suggest S under mTPI, a now suboptimal decision under mTPI-2. More
discussion about Figure 3 will follow next. The full algorithm of mTPI-2 is given below, assuming patients
are enrolled in cohorts of size ≥ 1.
11
Optimal decision rule: Suppose that the current dose is d, d ∈ {1, · · · , D} candidate doses. After the
toxicity outcomes of the most recent patient cohort are observed, denote (xd, nd) the current observed
trial data. Select the dose for treating the next cohort among {(d − 1), d, (d + 1)} based on the
optimal rule DmTPI−2 in Corollary 1. There are two exceptions: if d = 1, the next available doses are
{d, (d+ 1)}; if d = D, the next available doses are {(D − 1), D}.
Trial stopping rule: Assume n1 > 0. If Pr(p1 > pT | xd, nd) > ξ, for a large probability ξ, say 0.95,
terminate the trial due to excessive toxicity. Otherwise, terminate the trial when the maximum sample
size is reached. In the special case of cohorts of size 1, do not apply the stopping rule Pr(p1 > pT |
xd, nd) > ξ, until three or more patients have been evaluated at a dose.
MTD selection: At the end of the trial, select the dose as the estimated MTD with the smallest difference
|pˆ∗d−pT | among all the doses d for which nd > 0 and Pr(pd > pT |xd, nd) < ξ. Here pˆ∗d is the isotonically
transformed posterior mean of pd, the same as that in the mTPI design (Ji et al., 2010). If two or
more doses tie for the smallest difference, perform the following rule. Let p∗ denote the transformed
posterior mean pˆ∗d of the tied doses.
• If p∗ < pT , choose the highest dose among the tied doses.
• If p∗ > pT , choose the lowest dose among the tied doses.
4 Results
4.1 Decision Tables With Bayes Factors
As an interval design, both mTPI and mTPI-2 generate a set of decisions based on the input values pT , 1,
and 2 from physicians. They are summarized in a tabular format, e.g., those in Figure 3. Together, three
values define the equivalence interval (pT − 1, pT + 2) where any dose with a toxicity probability falling
into the interval can be considered as an MTD. Doses with toxicity probabilities outside the interval are
considered either too low or too high. In a dose-finding trial aiming at identifying the MTD, the decision
table can be precalculated for any values of pT ∈ (0, 1) and 1, 2  pT , and a sample size which determines
column number of the table. Suppose a sample size maxN is decided for the trial. For each enumerated
integer pairs, (x, n), 0 ≤ x ≤ n ≤ maxN , the decision DmTPI-2 ∈ {D,S,E} is precalculated.
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Figures 3 (a) shows an example of the decision tables under both designs for pT = 0.3 and a sample size
of 12. As can be seen, the main improvement of the mTPI-2 design over mTPI is the precise and “faithful”
decisions that reflect physicians input. For example, unlike mTPI where a decision S is given when xd = 3
toxicity events are observed out of nd = 6 patients, mTPI-2 recommends D, to de-escalate. Similarly, when
xd = 2 and nd = 9, the decision becomes E for mTPI-2 instead of S for mTPI. In essence, mTPI-2 becomes
a more “nimble” design due to the effort in blunting the Ockham’s razor. Specifically, mTPI favors the EI
and the decision S, to stay, simply because the equivalence interval has the shortest length and is preferred
in the Bayesian inference due to the Ockham’s razor. In contrast, mTPI-2 avoids the Ockham’s razor by
having equal-lengthed intervals. Therefore, in Figures 3(a) the mTPI-2 design shows fewer S, more D’s and
E’s.
Figure 3(b) shows the distribution of different decisions between mTPI-2 and mTPI for different pT
values and a large sample size of 30. As can be seen, all the differences are related to changing the decision
S in mTPI to not S (D, E, or DU) in mTPI-2. In general, many S decisions are changed to D or E,
corresponding to the green and blue bars, respectively. Also, when pT < 0.2, there are no green bars (hence
no change from S to E), which seems to be sensible since escalation is less likely when pT < 0.2. In addition,
when pT ≤ 0.2, some S decisions are changed to DU (red bars). That is, some “stay” decisions in mTPI
are changed to a composite decision in mTPI-2, which says that first, “De-escalate” and second, the current
dose is deemed too toxic and will be removed from the trial. This is a major modification on the dosing
decision.
We look into why there is such a big change. For example, such a change occurs when pT = 0.1 and
xd = 3 out of nd = 12 patients experience DLT. Under mTPI, the three intervals are (0, 0.05), (0.05, 0.15),
and (0.15, 1). Intuitively, the empirical toxicity rate equals xd/nd = 0.25, which is much higher than pT = 0.1.
So D, de-escalate, should be preferred. However, based on mTPI the UPM for S is the largest. The main
reason is that the posterior distribution of pd is Beta(4, 10) given data (xd = 3, nd = 12), which has a very
light right tail and puts tiny probability mass when pd > 0.7. This allows Ockham’s razor to sharply penalize
the right interval (0.15, 1), which is of length 0.85. In contrast, the EI (0.05, 0.15) only has a length of 0.15.
As a consequence, the UPM value for each of the three intervals, defined as the ratio of interval’s posterior
probability mass and interval length, favors the shorter interval (0.05, 0.15) instead of (0.15, 1), even though
the posterior distribution puts most mass above 0.15. Therefore, mTPI gives an S for (xd = 3, nd = 12).
However, the mTPI-2 design blunts the Ockham’s razor and uses sub-intervals with equal length. Based on
the new statistical framework under mTPI-2, the winning subinterval is (0.25, 0.35) and the optimal decision
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is D. In addition, under mTPI-2 the safety rule is invoked and therefore U is added. In the case of mTPI,
since the decision is S, the safety rule is not even evaluated (mTPI does not evaluate the safety rule unless
the decision is D). For these reasons, when xd = 3 and nd = 12 at a given dose d, mTPI would stay (S) and
mTPI would de-escalate and remove dose d from the trial (due to high toxicity). This example shows that
mTPI-2 is a safer design than mTPI.
In Figure 3(c) we show that the changes from mTPI decisions to mTPI-2 decisions are all compatible
with the empirical toxicity rate xd/nd. That is, mTPI-2 would only change S to E when the empirical rate
is lower than pT , and S to D when the empirical rate is higher than pT .
Due to the principled decision-theoretic framework, mTPI-2 calculates the posterior probability Pr(md =
Mi | {xd, nd}) for each of the intervals, Mi ∈ {LI,EI,HI}. Naturally, the Bayes factor (BF) between any
two intervals can be calculated as
BFij =
Pr(md = Mi | {xd, nd})
Pr(md = Mj | {xd, nd}) ,
assuming equal prior probability for each model Mi. A value close to 1 means there is only weak evidence
supporting one model or the other. In mTPI-2, in addition to provide the winning decision in the table, we
also display the BF of the winning decision versus the decision with the second largest posterior probability.
Therefore, all those BF’s are greater than 1 but a value close to 1, say < 1.05 indicates uncertainty in the
decision. Due to small sample sizes for phase I trials, such weak decisions are not uncommon as can be seen
in Table 2 below.
4.2 Simulation Studies
We conduct a comprehensive study that evaluates the performance of mTPI-2 and mTPI. Powered by
crowd sourcing, we include a study based on 1,774 scenarios and 6,013,460 simulated trials, generated by 71
independent users of our existing tool, NGDF (Yang et al., 2015). NGDF is a web tool that allows users to
design and simulate dose-finding trials based on various methods, including 3+3, CRM, and mTPI. We take
the scenarios and simulation settings (including sample size and number of simulated trials per scenario) and
simulate trials based on mTPI and mTPI-2. Therefore, the scenarios we use are from NGDF users, which
constitute a crowd-sourcing exercise. Crowd sourcing typically allows objective and unbiased assessment
of various methods, since the evaluators are a large number of different users, rather than the inventors
themselves.
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(a) A combined decision table for mTPI and mTPI-2.
(b) Changes between mTPI and mTPI-2 for various pT values. (c) A box-plot of xd/nd − pT values for the changes.
Figure 3: An example of the optimal decision tables for mTPI and mTPI-2. (a) presents decisions for both
mTPI and mTPI2. For each “Number of Patients” (column), there are two subcolumns listing the decisions
of mTPI and mTPI2 side by side. Here, the target toxicity probability pT = 0.30 and 1 = 2 = 0.05. (b)
summarizes the differences in decisions between mTPI and mTPI2 with breakdowns of different pT values.
For example, the blue bar denotes a change from decision S in mTPI to decision E in mTPI-2. (c) Boxplots
of (xd/nd−pT ) for the decisions that are changed in mTPI. The plots show that when xd/nd < pT , decisions
S are changed to E; when xd/nd > pT , decisions S are changed to D or DU .
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Table 2: Decisions in mTPI-2 along with Bayes’ factors. For any decision that is not “U”, a Bayes factor
(BF) is provided comparing the winning decision and the second most likely decision. The BF value here is
always greater than 1 since we calculated the BF of the winning decision versus the second best decision. A
BF value closer to 1 indicates weaker evidence supporting the winning decision.
Number of Patients
3 (BF) 6 (BF) 9 (BF) 12 (BF)
N
u
m
b
er
of
D
L
T
s
0 E (2.12) E (4.47) E (9.38) E (19.56)
1 S (1.02) E (1.29) E (2.34) E (4.8)
2 D (2.32) S (1.04) E (1.12) E (1.64)
3 U D (1.68) S (1.06) S (1.03)
4 U D (1.45) S (1.08)
5 U U D (1.42)
6 U U D (2.73)
7 U U
8 U U
9 U U
10 U
11 U
12 U
We compare both methods in terms of reliability and safety, as described in Ji and Wang (2013). In
particular, reliability is the average percentage that the true MTD is selected at the end of the trial, for a
given scenario and across all the simulated trials; and safety is the average percentage of patients treated
at or below the true MTD, for a given scenario and across all the simulated trials. So for each method, we
obtain 1,774 reliability values, one for each scenario. We then take pair-wise differences between any two
methods in their reliability values for the same scenario, and plot the boxplots of the differences in the left
half of Figure 4. Each boxplot corresponds to a unique pT value of the simulated trials. In the right half we
show the boxplots for safety comparisons in the same manner.
Figure 4 shows that when pT ≤ 0.2, mTPI is slightly more reliable in identifying the true MTD than
mTPI-2. However, when pT > 0.2, mTPI-2 is more reliable. What stands out is that mTPI-2 is always safer
than mTPI regardless of the pT values, which means that mTPI-2 has less chance of assigning patients to
overly toxic doses than mTPI. In practice, mTPI-2 and mTPI are both easy to implement, only requiring 1)
generating dose-assignment decision tables (e.g., in Figure 3a) prior to trial initiation and 2) following the
decisions in the table during the course of the trial.
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Figure 4: Boxplots comparing the reliability and safety of mTPI and mTPI-2.
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5 Software
We have implemented mTPI-2 as an online tool at www.compgenome.org/NGDF. It only requires a web
browser, such as Google Chrome, to access. The same website hosts mTPI, 3+3, and a version of CRM
which allows head-to-head comparison between mTPI-2 and these designs. There is no need to download or
maintain any software package, and the web tool can be accessed anywhere via internet. In our experience,
the web tool runs successfully on a tablet such as iPad or a smart phone such as iphone. This capability
allows investigators to use the design with great flexibility. A detailed user manual is provided on the website
to assist new users.
6 Discussion
We present mTPI-2, an improved mTPI design, to reduce the effect from the Ockham’s razor in the posterior
inference. The mTPI-2 design is based on formal Bayesian decision theoretic framework, adjusting for
Ockham’s razor. It mitigates some suboptimal decisions in mTPI and provides theoretically optimal and
intuitively sound decision rules. As a result, mTPI-2 makes more refined actions that allow more efficient
exploration of different doses in the dose finding process.
The mTPI-2 design hinges on user-provided quantities, pT , 1 and 2. It treats any dose with toxicity
probability smaller than (pT−1) or larger than (pT +2) as being lower or higher than the MTD, respectively.
Therefore, these two values are the key input of the design and must be elicited from physicians. For example,
one can ask the physician what the highest toxicity rate is that would still warrant a dose escalation (pT −1)
and the lowest rate (pT + 2) that would warrant a dose de-escalation. In this paper, we consider 1 = 2.
Intuitively, when the two ’s are not equal, the decisions can be altered in a nonsymmetric way such as
allowing more escalation than de-escalation or the opposite. This is an ongoing research direction that we
are currently pursuing.
We focus on the comparison between mTPI and mTPI-2 in this paper. For interested readers desired to
compare mTPI-2 to the 3+3 design (Storer, 1989) or the continual reassessment method (CRM, O’Quigley
et al. (1990)), we refer to Ji and Wang (2013) and Yang et al. (2015) who compared mTPI to 3+3 and CRM
through extensive simulation studies, which serves as an indirect comparison to mTPI-2.
Innovatively, mTPI-2 is able to provide Bayes factors for each decision so that investigators can assess the
uncertainty behind it. These Bayes factors may provide additional use for future work, such as allowing for
randomization between two different decisions when the value of Bayes factor comparing the two decisions
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is very close to 1.
The size of the equivalence interval serves as an “effect size” for phase I dose-finding trials. This is an
added benefit of interval-based designs, such as mTPI and mTPI-2. A narrower equivalence interval implies
that the MTD must be identified with more precision, and therefore demands a larger sample size. Also the
sample size will depend on the number of doses in the trial and the cohort size, see (Ji and Wang, 2013) for
a discussion. We intend to address the sample size issue in a future work.
References
Berger, J. (1988). 0.(1985), statistical decision theory and bayesian analysis.
Cheung, Y. K. and Chappell, R. (2002). A simple technique to evaluate model sensitivity in the continual
reassessment method. Biometrics 58, 671–674.
Good, I. J. (1967). A bayesian significance test for multinomial distributions. Journal of the Royal Statistical
Society. Series B (Methodological) pages 399–431.
Ivanova, A., Flournoy, N., and Chung, Y. (2007). Cumulative cohort design for dose-finding. Journal of
Statistical Planning and Inference 137, 2316–2327.
Jefferys, W. H. (1990). Bayesian analysis of random event generator data. Journal of Scientific Exploration
4, 153–169.
Jefferys, W. H. and Berger, J. O. (1992). Ockham’s razor and bayesian analysis. American Scientist 80,
64–72.
Ji, Y., Li, Y., and Bekele, B. N. (2007). Dose-finding in phase i clinical trials based on toxicity probability
intervals. Clinical Trials 4, 235–244.
Ji, Y., Liu, P., Li, Y., and Bekele, B. N. (2010). A modified toxicity probability interval method for dose-
finding trials. Clinical Trials page 1740774510382799.
Ji, Y. and Wang, S.-J. (2013). Modified toxicity probability interval design: a safer and more reliable method
than the 3+ 3 design for practical phase i trials. Journal of Clinical Oncology 31, 1785–1791.
Johnson, N. L., Kotz, S., and Balakrishnan, N. (2002). Continuous multivariate distributions, volume 2
(page 238), volume 59. New York: John Wiley & Sons.
19
Liu, S. and Yuan, Y. (2015). Bayesian optimal interval designs for phase i clinical trials. Journal of the
Royal Statistical Society: Series C (Applied Statistics) 64, 507–523.
MacKay, D. J. (1992). Bayesian methods for adaptive models. PhD thesis, California Institute of Technology.
O’Quigley, J., Pepe, M., and Fisher, L. (1990). Continual reassessment method: a practical design for phase
1 clinical trials in cancer. Biometrics pages 33–48.
Oron, A. P., Azriel, D., and Hoff, P. D. (2011). Dose-finding designs: the role of convergence properties. The
international journal of biostatistics 7, 1–17.
Storer, B. E. (1989). Design and analysis of phase i clinical trials. Biometrics pages 925–937.
Swaminathan, A. (2007). Convexity of the incomplete beta functions. Integral Transforms and Special
Functions 18, 521–528.
Thorburn, W. M. (1918). The myth of occam’s razor. Mind 27, 345–353.
Yang, S., Wang, S.-J., and Ji, Y. (2015). An integrated dose-finding tool for phase i trials in oncology.
Contemporary clinical trials 45, 426–434.
20
Appendix
A. Proof of Theorem 1
Recall that S(Mi) is the size of interval length for model Mi, i ∈ {E,S,D}. For example, for ME , S(ME) =
pT − 1.
It suffices to show that the decisions rule DmTPI maximizes E((1 − `(i,Mj)) | {xd, nd}), the posterior
expected utility, where utility is defined as one minus the 0-1 loss, i.e., (1− `(i,Mj)). The posterior expected
utility for action i ∈ {E,S,D}, at dose d is given by
L(i, d) =
∑
j∈{E,S,D}
`(i,Mj)p (Mj | (xd, nd))
∝
∑
j∈{E,S,D}
`(i,Mj)
∫
p(xd | nd, pd)p(pd |Mj)p(Mj)dpd
=
∫
p(xd | nd, pd)p(pd |Mi)p(Mi)dpd
∝
∫ hi
li
1
S(Mi)
pxdd (1− pd)nd−xddpd
∝ Pr(Mi | {xd, nd})
S(Mi)
= UPM(i, d)
Therefore, the decision rule (2) given by
DmTPI = arg max
i∈{E,S,D}
UPM(i, d) (7)
maximizes the posterior expected utility, which is equivalent to minimizing the posterior expected 0-1 loss.
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B. Rate of Incomplete Beta Function
We only need to consider the posterior probability of model Mi in the calculation of UPM, i.e.,
Pr(Mi | xd, nd) ∝ 1
S(Mi)
∫ hi
li
pxdd (1− pd)nd−xddpd
∝ Ihi(xd + 1, nd − xd + 1)− Ili(xd + 1, nd − xd + 1)
hi − li (8)
where
Ix(p, q) =
1
B(p, q)
∫ x
0
tp−1(1− t)q−1dt
is the incomplete beta function, with
B(p, q) =
∫ 1
0
tp−1(1− t)q−1dt.
Based on Johnson et al. (2002),
Ix(p, q) ≈ Φ(z)
where
z =
k
|q − 0.5− n(1− x)|
{
2
1 + (6n)−1
[
(q − 0.5) log
{
q − 0.5
n(1− x)
}
+ (p− 0.5) log
{
p− 0.5
nx
}]}1/2
, (9)
n = nd − 1 and k = nd − xd − 1/3 − (nd + 1/3)(1 − x). When xd = 3 and nd = 6, the incomplete beta
function can be shown to be approximated by
Φ(sgn(x− 0.5)) ∗
√
−7 log(x(1− x))).
Based on Feller (1968), this can be approximated by
I(x > 0.5) ∗ 1
2
+ sgn(x− 0.5) ∗ e
−y2/2
√
2piy
, y =
√
−7 log(x(1− x)),
which equals
I(x > 0.5) ∗ 1
2
+ sgn(x− 0.5) ∗ {x(1− x)}
1/14√−14pi log(x(1− x)) .
A numerical evaluation reveals that when x takes values at 0.25, 0.35, and near 1, the expression of (8) favors
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model MD in which hi = 1 and li = 0.35 over model MS in which hi = 0.35 and li = 0.25. Unfortunately,
there is no general conclusion on the value of (8) for any xd and nd values, which makes the theoretical
derivation difficult. The above derivation pushes forward the theoretical development for the incomplete
beta function in that it gives the ratio of (x(1 − x))1/14/√−log(x(1− x)). However, the entire function if
not monotone with a mode at 0.5, which makes it difficult to evaluate the magnitude of (8) as a difference of
two incomplete beta functions. It is known that the analytic expression of incomplete beta function is still
an open research question (Swaminathan, 2007). Therefore, we leave the further theoretical development to
future work.
23
